z-logo
Premium
Chronic hepatitis B increases mortality and complexity among HIV ‐coinfected patients in South Africa: a cohort study
Author(s) -
Velen K,
Charalambous S,
Innes C,
Churchyard GJ,
Hoffmann CJ
Publication year - 2016
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12367
Subject(s) - medicine , interquartile range , hazard ratio , confidence interval , hepatitis b virus , hepatitis b , chronic hepatitis , cohort , cohort study , human immunodeficiency virus (hiv) , immunology , gastroenterology , virus
Objectives To assess the effect of chronic hepatitis B on survival and clinical complexity among people living with HIV following antiretroviral therapy (ART) initiation. Methods We evaluated mortality and single‐drug substitutions up to 3 years from ART initiation (median follow‐up 2.75 years; interquartile range 2–3 years) among patients with and without chronic hepatitis B ( CHB ) enrolled in a workplace HIV care programme in South Africa. Results Mortality was increased for CHB patients with hepatitis B virus ( HBV ) DNA levels > 10 000 copies/mL (adjusted hazard ratio 3.1; 95% confidence interval 1.2–8.0) compared with non‐ CHB patients. We did not observe a similar difference between non‐ CHB patients and those with CHB and HBV DNA < 10 000 copies/ mL (adjusted hazard ratio 0.70; 95% confidence interval 0.2–2.3). Single‐drug substitutions occurred more frequently among coinfected patients regardless of HBV DNA level. Conclusions Our findings suggest that CHB may increase mortality and complicate ART management.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here